Widely used:Recently Viewed
Clear All
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$18 Mln
P/E Ratio
--
P/B Ratio
0.77
Industry P/E
--
Debt to Equity
0
ROE
-0.66 %
ROCE
--
Div. Yield
0 %
Book Value
1.08
EPS
--
CFO
CA$-38.89 Mln
EBITDA
CA$-47.34 Mln
Net Profit
CA$-73.57 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Immunoprecise Antibodies (IPA)
| -6.51 | -13.31 | -4.56 | -76.39 | -52.71 | -30.62 | -- |
|
BSE Sensex*
| -5.65 | -3.07 | -9.18 | 0.22 | 9.95 | 17.63 | 9.82 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|
|
Immunoprecise Antibodies (IPA)
| -67.18 | -2.80 | -64.15 | 3,295.41 | -13.80 | 9.42 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to... support the development of therapeutic antibodies and are known for solving industry challenges. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; peptide production for subsequent antibody discovery campaign; B cell select platform, which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. In addition, it provides phage display, a custom immune library; CAR development, an adaptable antibody, which allows the inclusion of functional data early in the screening funnel; antibody sequencing; and assay development. Further, it offers a profiling toolset for antibody lead candidates; and in vitro analytical tools for the study of quality attributes. Additionally, it provides LucinaTech, an antibody humanization to identify framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; antibody chimerization for cloning and production of antibody domain; Eurofins preclinical services; hybrid service model designed to reduce time and risk with custom applications; breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts; and protein manufacturing services. The company was founded in 1983 and is headquartered Read more
CEO, President & Non-Independent Director
Dr. Jennifer Lynne Bath Ph.D.
CEO, President & Non-Independent Director
Dr. Jennifer Lynne Bath Ph.D.
Headquarters
Victoria, BC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Immunoprecise Antibodies Ltd (IPA) stood at $ 72 Mln as on 31-Oct-24
The share price of Immunoprecise Antibodies Ltd (IPA) is $0.36 (NASDAQ) as of 14-Mar-2025 16:27 EDT. Immunoprecise Antibodies Ltd (IPA) has given a return of -52.71% in the last 3 years.
Immunoprecise Antibodies Ltd (IPA) has a market capitalisation of $ 18 Mln as on 14-Mar-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Immunoprecise Antibodies Ltd (IPA) is 0.77 times as on 14-Mar-2025, a 13% premium to its peers’ median range of 0.68 times.
Since, TTM earnings of Immunoprecise Antibodies Ltd (IPA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Immunoprecise Antibodies Ltd (IPA) and enter the required number of quantities and click on buy to purchase the shares of Immunoprecise Antibodies Ltd (IPA).
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving industry challenges. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; peptide production for subsequent antibody discovery campaign; B cell select platform, which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. In addition, it provides phage display, a custom immune library; CAR development, an adaptable antibody, which allows the inclusion of functional data early in the screening funnel; antibody sequencing; and assay development. Further, it offers a profiling toolset for antibody lead candidates; and in vitro analytical tools for the study of quality attributes. Additionally, it provides LucinaTech, an antibody humanization to identify framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; antibody chimerization for cloning and production of antibody domain; Eurofins preclinical services; hybrid service model designed to reduce time and risk with custom applications; breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts; and protein manufacturing services. The company was founded in 1983 and is headquartered
The CEO & director of Dr. Jennifer Lynne Bath Ph.D.. is Immunoprecise Antibodies Ltd (IPA), and CFO & Sr. VP is Dr. Jennifer Lynne Bath Ph.D..
There is no promoter pledging in Immunoprecise Antibodies Ltd (IPA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Immunoprecise Antibodies Ltd (IPA) | Ratios |
|---|---|
|
Return on equity(%)
|
-81.74
|
|
Operating margin(%)
|
-59.42
|
|
Net Margin(%)
|
-113.43
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Immunoprecise Antibodies Ltd (IPA) was $0 Mln.
$-0.04
(
